Inbiomotion announces approval of NSABP B34 validation study by National Cancer Institute (NCI) and the NRG groups

Barcelona, Spain, 2018 - Inbiomotion S.L., a biotech company specialized in the development of companion diagnostics for the use of bone modifying agents, has just announced that has been granted of access to the NSABP B34 trial by the National Cancer Institute and NRG Oncology Group, US, to validate its proprietary biomarker.

The company is focused on the development of a new companion diagnostic to identify patients that benefit from those harm from the use of a bisphosphonate for breast cancer adjuvant treatment.